Perfil de fragilidad que excluye la dosis completa de CHC-Bv en ALCL: ECOG ≥3, OR (nivel ≥75 con G8 ≤14), O...
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | RF-ALCL-FRAILTY-AGE |
|---|---|
| Tipo | Señal de alerta |
| Situación | reviewed 2026-04-27 | pending_clinical_signoff |
| Enfermedades | DIS-ALCL |
| Fuentes | SRC-ESMO-PTCL-2024 SRC-NCCN-BCELL-2025 |
Origen de la bandera roja
| Definición | Frailty profile precluding full-dose CHP-Bv in ALCL: ECOG ≥3, OR (age ≥75 with G8 ≤14), OR composite frailty (age ≥70 + Charlson ≥3 + albumin <3.5). Triggers de-escalation to brentuximab-vedotin monotherapy or attenuated CHP-Bv (50-75% doses). |
|---|---|
| Dirección clínica | decreciente |
| Categoría | edad de fragilidad |
Lógica de activación
{
"any_of": [
{
"comparator": ">=",
"finding": "ecog",
"threshold": 3
},
{
"all_of": [
{
"comparator": ">=",
"finding": "age",
"threshold": 75
},
{
"comparator": "<=",
"finding": "g8_score",
"threshold": 14
}
]
},
{
"all_of": [
{
"comparator": ">=",
"finding": "age",
"threshold": 70
},
{
"comparator": ">=",
"finding": "charlson_score",
"threshold": 3
},
{
"comparator": "<",
"finding": "albumin_g_dl",
"threshold": 3.5
}
]
}
],
"type": "composite_score"
}
Notas
G8 (Geriatric-8) screening tool validated in oncology; ≤14 indicates need for full CGA. ALCL is unusual among PTCLs in that brentuximab monotherapy alone (1.8 mg/kg q3w) is meaningfully active in frail unfit patients (~40-60% ORR data extrapolated from r/r ALCL). Avoid vincristine + brentuximab combo when neuropathy already present. AlloHCT typically off-table; autoSCT consolidation post-CR remains reasonable in selected fit-elderly.
Utilizado por
No se encuentran referencias inversas en el corpus YAML.